Pharmaron Beijing Co

Pharmaron Beijing Co FCF Margin

The Free Cash Flow Margin of Pharmaron Beijing Co (300759.SZ) as of Nov 6, 2026 is 3.92 %. In the previous year, Free Cash Flow Margin was 4.37 % — a change of -10.32% (lower).

FCF Margin

3.92 %

YoY

-10.32%

Last updated:

Free Cash Flow Margin of Pharmaron Beijing Co is 2025 3.92 % . Free Cash Flow Margin of Pharmaron Beijing Co was 2024 4.37 % . It decreases by -10.32% lower compared to the previous year.

The Pharmaron Beijing Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
5.15 CNY
Jan 1, 2019
4.90 CNY
Jan 1, 2020
6.48 CNY
Jan 1, 2021
-0.47 CNY
Jan 1, 2022
-7.86 CNY
Jan 1, 2023
-0.97 CNY
Jan 1, 2024
4.37 CNY
Jan 1, 2025
3.92 CNY
The Pharmaron Beijing Co FCF Margin history
YEARFCF MarginYoY
3.92 %-10.32%
4.37 %-550.70%
-0.97 %-87.68%
-7.86 %+1,582.59%
-0.47 %-107.21%
6.48 %+32.38%
4.90 %-4.91%
5.15 %-130.89%
-16.67 %-66.76%
-50.16 %+1,267.24%
-3.67 %-58.46%
-8.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmaron Beijing Co Stock analysis

What does Pharmaron Beijing Co do? Pharmaron Beijing Co Ltd generates revenue through four business segments. The Laboratory Services segment offers laboratory chemistry, drug metabolism, pharmacokinetics, absorption, distribution, metabolism, and excretion testing, biology, safety assessment, and discovery of biological agents. The CMC Service segment provides process development, preform production, and analysis for drug manufacturing. The Clinical Development Service segment delivers clinical research, on-site management organization, regulatory biological analysis, and radioactive labeling scientific services. The Biologics and CGT Services segment focuses on macromolecular drug discovery, development, and production, alongside cell gene therapy method development. These services are primarily purchased by pharmaceutical companies and biotechnology firms engaged in drug discovery and development processes. Pharmaron Beijing Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmaron Beijing Co stock

Free Cash Flow Margin of Pharmaron Beijing Co is 3.92 % in 2025.

Free Cash Flow Margin of Pharmaron Beijing Co changed from 4.37 % to 3.92 %, representing a -10.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Pharmaron Beijing Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Pharmaron Beijing Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Pharmaron Beijing Co

All Key Metrics — Pharmaron Beijing Co